Wall Street Zen Upgrades Sotera Health (NASDAQ:SHC) to Strong-Buy

Sotera Health (NASDAQ:SHC) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other brokerages have also recently commented on SHC. Barclays boosted their target price on shares of Sotera Health from $19.00 to $22.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. increased their price target on shares of Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. The Goldman Sachs Group began coverage on shares of Sotera Health in a research note on Friday, June 5th. They issued a “buy” rating and a $20.00 price objective on the stock. Citigroup boosted their price objective on shares of Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of Sotera Health in a research note on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Sotera Health has an average rating of “Moderate Buy” and an average price target of $21.50.

Sotera Health Stock Performance

SHC opened at $19.27 on Friday. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80. Sotera Health has a 52-week low of $13.09 and a 52-week high of $19.85. The firm has a market cap of $5.50 billion, a P/E ratio of 33.81 and a beta of 1.77. The business’s fifty day moving average is $18.12 and its 200-day moving average is $16.40.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The business had revenue of $321.38 million during the quarter, compared to the consensus estimate of $309.70 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. Sotera Health’s revenue for the quarter was up 9.2% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Sell-side analysts expect that Sotera Health will post 0.86 EPS for the current fiscal year.

Insider Activity

In other news, Chairman Michael B. Jr. Petras sold 850,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the sale, the chairman directly owned 3,969,393 shares in the company, valued at approximately $73,433,770.50. This trade represents a 17.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael P. Rutz sold 150,000 shares of Sotera Health stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the sale, the insider directly owned 334,279 shares in the company, valued at $6,297,816.36. This trade represents a 30.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 1,294,515 shares of company stock valued at $23,999,528. Insiders own 15.36% of the company’s stock.

Institutional Trading of Sotera Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Sotera Health in the 2nd quarter valued at $428,635,000. Sculptor Capital LP bought a new stake in Sotera Health during the 2nd quarter worth $426,000,000. Vanguard Group Inc. grew its position in Sotera Health by 16.7% during the 4th quarter. Vanguard Group Inc. now owns 19,228,375 shares of the company’s stock worth $339,189,000 after acquiring an additional 2,756,583 shares during the last quarter. Sachem Head Capital Management LP increased its holdings in Sotera Health by 47.2% in the 4th quarter. Sachem Head Capital Management LP now owns 11,645,000 shares of the company’s stock worth $205,418,000 after purchasing an additional 3,735,000 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Sotera Health by 35.3% in the 1st quarter. Janus Henderson Group PLC now owns 9,162,191 shares of the company’s stock worth $131,413,000 after purchasing an additional 2,390,132 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.